人のウォール街のアナリストによると、NuGen Medical Devices Inc.の収益見積もりは$から$の範囲です。
NuGen Medical Devices Inc.の収益品質スコアはどれくらいですか?
NuGen Medical Devices Inc.の収益品質スコアは/です。このスコアは、収益性、成長、キャッシュ生成と資本配分、レバレッジの4つの次元に基づいています。
NuGen Medical Devices Inc.はいつ収益を報告しますか?
NuGen Medical Devices Inc.の次の収益報告は2026-08-31に予定されています
NuGen Medical Devices Inc.の予想収益はいくらですか?
ウォール街のアナリストによると、NuGen Medical Devices Inc.の予想収益は$です。
NuGen Medical Devices Inc.は収益予想を上回りましたか?
NuGen Medical Devices Inc.の最近の収益は$で、予想を。
主要データ
前終値
$0.0095
始値
$0.0146
当日レンジ
$0.0095 - $0.0146
52週レンジ
$0.0095 - $0.0467
取引高
100.0K
平均取引高
1.7K
配当利回り
--
1株当たり利益(TTM)
-0.04
時価総額
$2.1M
NUGEN MED DEVICES INC.とは何ですか?
Nugen Medical Devices, Inc. engages in the development of needle-free devices to administer therapeutics subcutaneously. The firm is engaged in marketing and selling its InsuJet needle-free injection system designed to improve the lives of millions of diabetics. Its principal business is the research, development and commercialization of needle-free injection devices and systems for the administration of subcutaneous medication. The company is developing products using its needle-free delivery technology in several fields including, but not limited to, diabetes, semaglutide, growth and fertility hormone, as well as deoxyribonucleic acid (DNA) and conventional/pediatric vaccines. The company is focusing its development efforts on needle free devices in the area of liquid jet delivery through the InsuJet platform. The firm's InsuJet technology platform is based on jet-stream administration of liquid drugs. The firm manufactures and commercializes needle-free injection systems and sells in over 40 countries globally.